Genomic Health Announces Plans to Launch Liquid Biopsy Mutation Panel in 2016

Genomic Health, Inc. announced plans to launch its first liquid biopsy test, Oncotype SEQ™, in mid-2016. The test is a blood-based mutation panel that uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal cancer. As a fit-for-purpose panel, Oncotype SEQ is designed to meet the needs of community oncologists by delivering actionable clinical information to the cancer patients.

"Non-invasive liquid biopsy tests offer a significant opportunity to transform the management of cancer, and it is our goal to deliver multiple products across oncology and urology beginning with Oncotype SEQ," said Phil Febbo, M.D., chief medical officer of Genomic Health. "We believe we are well positioned to lead this new market given our experience developing cancer tests that are optimized for clinical utility and patient access, along with our operational expertise and unmatched commercial channel."

Oncotype SEQ represents the first of several liquid biopsy tests that Genomic Health plans to deliver through the introduction of its Oncotype IQ™ Genomic Intelligence Platform. This portfolio of genomic tests and services currently consists of the Company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. In the future, Genomic Health plans to expand its test portfolio through both internal product development and partnerships to include additional tissue and liquid-based tests for the management and monitoring of multiple cancer types.